Skip to Main Content

An official website of the United States government

Coffee, tea, caffeine and the risk of cancer

Principal Investigator
Name
Mia Hashibe
Institution
University of Utah
Email
About this CDAS Project
Study
PLCO (Learn more about this study)
Project ID
2011-0052
Initial CDAS Request Approval
Apr 4, 2011
Title
Coffee, tea, caffeine and the risk of cancer
Summary
The association between coffee intake and various cancers have been studied over the last 35 years. In a Japanese cohort study, coffee intake was associated with a decrease in overall mortality, and inversely associated, though weakly, with overall cancer mortality among women. Recent studies have been suggestive of protective effects of coffee against head and neck cancer, esophageal SCC, breast cancer, endometrial cancer, kidney cancer, and glioma. On the other hand, some cancers are thought to have no association with coffee intake (esophageal adenocarcinoma, stomach cancer, lung cancer, ovarian cancer, prostate cancer, bladder cancer, testicular cancer and thyroid cancer). Tea intake may also be protective against ovarian and breast cancers. Considering that coffee and tea consumption is a highly prevalent lifestyle factor in the world, it is of interest to clarify the role of coffee and tea in cancer overall and in specific cancer sites. It will also be of interest to determine whether caffeine, a component of both coffee and tea intake, is associated with cancer. Examining coffee, tea and caffeine intake in a cohort study where the exposure measurements occurred before the cancer diagnosis occurred is an ideal approach since many of the previous studies were case-control in design with the issue of recall bias. Thus we propose to examine the role of coffee, tea and caffeine intake for cancer in the PLCO study.
Aims

Specific aim 1: To examine whether coffee intake is associated with the risk of cancer overall, and with the risk of specific cancer sites. Hypothesis 1: Coffee intake is protective against the risk of cancers overall. Hypothesis 2: There are inverse associations between coffee and the risk of the following diseases: head and neck cancer, esophageal SCC, breast cancer, cervical cancer, endometrial cancer, kidney cancer, and glioma. Hypothesis 3: There are no associations between coffee and the risk of the following diseases: esophageal adenocarcinoma, stomach cancer, lung cancer, ovarian cancer, prostate cancer, bladder cancer, testicular cancer and thyroid cancer. Specific aim 2: To examine whether tea intake is associated with the risk of cancer overall, and with the risk of specific cancer sites. Hypothesis 4: Tea intake is not associated with cancer overall. Hypothesis 5: Tea consumption is protective against ovarian and breast cancer. Hypothesis 6: Tea consumption is not associated with head and neck cancer or lung cancer. Specific aim 3: To explore differences in cancer risk for caffeinated vs. decaffeinated tea/coffee and addition of sugar, artificial sweeteners, non-dairy creamer, cream and milk. Hypothesis 7: Caffeinated coffee or tea intake, but not decaffeinated coffee or tea intake will have protective effects against head and neck cancer, esophageal SCC, breast cancer, endometrial cancer, kidney cancer, and glioma. Hypothesis 8: Addition of sugar, artificial sweeteners, non-dairy creamer, cream and milk in coffee or tea will not affect the associations between coffee/tea and the risk of cancer. Specific aim 4: To assess whether caffeine intake is associated with cancer risk. Hypothesis 9: Caffeine intake is not associated with cancer overall or with any of the specific sites of cancer that have been associated with coffee or tea intake. We propose to exclude examination of pancreatic cancer, hepatocellular carcinoma, colorectal cancer and colorectal adenoma in this current proposal, since examining coffee and the risk of these cancers has already been proposed in other projects.

Collaborators

Fong Liu (UCLA School of Public Health)
Lisa Gren (Family and Preventive Medicine)
Saundra Buys (Huntsman Cancer Institute)
Zuo-Feng Zhang (UCLA School of Public Health)

Related Publications
  • Coffee, tea, caffeine intake, and the risk of cancer in the PLCO cohort.
    Hashibe M, Galeone C, Buys SS, Gren L, Boffetta P, Zhang ZF, La Vecchia C
    Br. J. Cancer. 2015 Sep; Volume 113 (Issue 5): Pages 809-16 PUBMED
  • Genome-wide meta-analysis identifies six novel loci associated with habitual coffee consumption.
    Coffee and Caffeine Genetics Consortium, Cornelis MC, Byrne EM, Esko T, Nalls MA, Ganna A, Paynter N, Monda KL, Amin N, Fischer K, Renstrom F, Ngwa JS, Huikari V, Cavadino A, Nolte IM, Teumer A, Yu K, Marques-Vidal P, Rawal R, Manichaikul A, ...show more Wojczynski MK, Vink JM, Zhao JH, Burlutsky G, Lahti J, Mikkilä V, Lemaitre RN, Eriksson J, Musani SK, Tanaka T, Geller F, Luan J, Hui J, Mägi R, Dimitriou M, Garcia ME, Ho WK, Wright MJ, Rose LM, Magnusson PK, Pedersen NL, Couper D, Oostra BA, Hofman A, Ikram MA, Tiemeier HW, Uitterlinden AG, van Rooij FJ, Barroso I, Johansson I, Xue L, Kaakinen M, Milani L, Power C, Snieder H, Stolk RP, Baumeister SE, Biffar R, Gu F, Bastardot F, Kutalik Z, Jacobs DR, Forouhi NG, Mihailov E, Lind L, Lindgren C, Michaëlsson K, Morris A, Jensen M, Khaw KT, Luben RN, Wang JJ, Männistö S, Perälä MM, Kähönen M, Lehtimäki T, Viikari J, Mozaffarian D, Mukamal K, Psaty BM, Döring A, Heath AC, Montgomery GW, Dahmen N, Carithers T, Tucker KL, Ferrucci L, Boyd HA, Melbye M, Treur JL, Mellström D, Hottenga JJ, Prokopenko I, Tönjes A, Deloukas P, Kanoni S, Lorentzon M, Houston DK, Liu Y, Danesh J, Rasheed A, Mason MA, Zonderman AB, Franke L, Kristal BS, International Parkinson’s Disease Genomics Consortium (IPDGC), North American Brain Expression Consortium (NABEC), UK Brain Expression Consortium (UKBEC), Karjalainen J, Reed DR, Westra HJ, Evans MK, Saleheen D, Harris TB, Dedoussis G, Curhan G, Stumvoll M, Beilby J, Pasquale LR, Feenstra B, Bandinelli S, Ordovas JM, Chan AT, Peters U, Ohlsson C, Gieger C, Martin NG, Waldenberger M, Siscovick DS, Raitakari O, Eriksson JG, Mitchell P, Hunter DJ, Kraft P, Rimm EB, Boomsma DI, Borecki IB, Loos RJ, Wareham NJ, Vollenweider P, Caporaso N, Grabe HJ, Neuhouser ML, Wolffenbuttel BH, Hu FB, Hyppönen E, Järvelin MR, Cupples LA, Franks PW, Ridker PM, van Duijn CM, Heiss G, Metspalu A, North KE, Ingelsson E, Nettleton JA, van Dam RM, Chasman DI
    Mol. Psychiatry. 2015 May; Volume 20 (Issue 5): Pages 647-656 PUBMED